Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
MedComm · 2024-02 · 5 (2)
DOI: 10.1002/mco2.474 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 04.02.2024. Verfasst von Xiaoting Luo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology Zhuhai People's Hospital Zhuhai Hospital Affiliated with Jinan University Zhuhai China. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 301 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the most common primary liver cancer with a high mortality rate. It is regarded as a significant public health issue because of its complicated pathophysiology, high metastasis, and recurrence rates. There are no obvious symptoms in the early stage of HCC, which often leads to delays in diagnosis. Traditional treatment methods such as surgical resection, radiotherapy, chemotherapy, and interventional therapies have limited therapeutic effects for HCC patients with recurrence or metastasis. With the development of molecular biology and immunology, molecular signaling pathways and immune checkpoint were identified as the main mechanism of HCC progression. Targeting these molecules has become a new direction for the treatment of HCC. At present, the combination of targeted drugs and immune checkpoint inhibitors is the first choice for advanced HCC patients. In this review, we mainly focus on the cutting‐edge research of signaling pathways and corresponding targeted therapy and immunotherapy in HCC. It is of great significance to comprehensively understand the pathogenesis of HCC, search for potential therapeutic targets, and optimize the treatment strategies of HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology Zhuhai People's Hospital Zhuhai Hospital Affiliated with Jinan University Zhuhai China.
- Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment Zhuhai People's Hospital Zhuhai Hospital Affiliated with Jinan University Zhuhai China.
- Department of Neurobiology School of Basic Medical Sciences Southern Medical University Guangzhou China.
ORCID-Profile: Shengni Hua
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024). Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm, 5(2). https://doi.org/10.1002/mco2.474
Vancouver
Luo X, He X, Zhang X, Zhao X, Zhang Y, Shi Y, et al. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm. 2024;5(2). doi:10.1002/mco2.474
BibTeX
@article{Luo2024,
author = {Luo, Xiaoting and He, Xin and Zhang, Xingmei and Zhao, Xiaohui and Zhang, Yuzhe and Shi, Yusheng and Hua, Shengni},
title = {Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy},
journal = {MedComm},
year = {2024},
volume = {5},
number = {2},
doi = {10.1002/mco2.474}
}
EUVIMED